Sanofi completes acquisition of Ablynx
On January 29, Sanofi announced its acquisition of Ablynx for $4.8 billion, and it announced the completion of the acquisition on June 19. The acquisition was one of two announced in January to advance its blood disorder portfolio. The other acquisition was of Bioverative. The Sanofi-Ablynx transaction highlights at the time of the announcement of the deal are shown below.
Sanofi is currently executing a soft integration of Bioverativ, whose acquisition the company closed in March. The company plans to begin Ablynx’s full integration in 2019. As discussed by Sanofi during its Q1 2018 earnings release, the company is focused on integrating Ablynx and Bioverativ in the near term. The Ablynx acquisition will add the company’s innovative nanobody platform and caplacizumab, a late-stage blood disorder asset, to Sanofi’s portfolio. The addition is not expected to have a neutral effect on Sanofi’s EPS in 2018 and 2019.
Ablynx stock delisted on June 13
The squeeze-out period started on May 22 and ended on June 12. Ablynx’s 2,893,201 shares, which included 7,163 ADSs (American depositary shares) and eight convertible bonds, were then tendered. All remaining securities have been deemed transferred to Sanofi. Ablynx shareholders retain the right to receive 45 euros per share or ADS and 393,700.78 euros per convertible bond.
On June 13, Ablynx stock was delisted from the Euronext Brussels regulated market, ADSs were delisted from the NASDAQ Global Select Market, and the company’s convertible bonds were delisted from the open-market Frankfurt Stock Exchange.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!